PT-141
Bremelanotide, a melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women.
How it works
Activates central MC3-R and MC4-R, modulating dopaminergic and oxytocinergic pathways involved in sexual desire.
Reported benefits
- Increases sexual desire independent of vascular response
- Onset within ~45 minutes, lasting hours
- Effective in both sexes in research settings
Dosage & administration
FDA label: 1.75 mg subcutaneously, no more than once per day or 8 per month.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
RECONNECT trials: bremelanotide for HSDD
Obstetrics & Gynecology · 2019
Significant increase in desire and reduction in distress vs placebo over 24 weeks.
Safety & warnings
- Transient nausea, flushing, headache
- Possible 1-2 mmHg increase in BP
- Skin darkening with repeated use
- Contraindicated in uncontrolled hypertension or CV disease
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
P41
Box of 10 · $195
Single vial · $390
Related guides
Semax
A Russian heptapeptide derived from ACTH(4-10) with neuroprotective and pro-cognitive activity.
Selank
A synthetic tuftsin analogue with anxiolytic, nootropic, and immunomodulatory effects.
DSIP
Delta Sleep-Inducing Peptide, a nonapeptide identified in cerebral venous blood of rabbits during sleep.